Registration for 2024 Annual Ataxia Conference is NOW OPEN! Early-bird discount available for a limited time. LEARN MORE!
Registration for 2024 Annual Ataxia Conference is NOW OPEN! Early-bird discount available for a limited time. LEARN MORE!
ACT will take place in Orlando, Florida, US from May 30th to June 1st, 2024. In response to the overwhelming success of previous ACT programs designed for medical fellows, the coming year’s class will also include a variety of healthcare professionals and industry professionals seeking to broaden their understanding of Ataxia. A certificate of completion will be awarded to each attendee who attends all sessions and completes all aspects of the program including pre-and-post tests and course feedback evaluations.
Applications are now closed. Interested industry members may reach out directly to aimee@ataxia.org for registration information.
Who is eligible?
Movement Disorder, Neuromuscular, and Genetics Fellows
What does the partial sponsorship include?
Partial sponsorship includes waived registration fees, lodging, and some meals on-site. Transportation and travel costs are not provided under the partial sponsorship.
How can I apply?
To be considered for partial sponsorship, please indicate your interest on the ACT application form.
Partial sponsorships are limited to a maximum of two fellows per institution.
When will I be notified of my application status?
Applications for partial sponsorship and attendance will be assessed in the sequence of their submission, with precedence granted to early-submitted applicants.
Due to the limited number of registration spaces and sponsorships, we highly encourage all interested to apply as soon as possible.
Notification of application and partial sponsorship status will be sent no later than November 14, 2023.
Junior Registration: $350
Applies to all medical residents and fellows.
Regular Registration: $500
Applies to all non-industry healthcare and medical professionals.
Corporate/Industry Registration: $1,500
Applies to all corporate and industry attendees.
*NAF DDC members please reach out to Aimee Alcott at aimee@ataxia.org for more information regarding registration benefits.
Additional travel information will be sent to accepted attendees. If you have specific travel questions, please contact Aimee Alcott at aimee@ataxia.org.
2024 ACT Applications Closed.
NAF’s Ataxia Clinical Training (ACT) program debuted in March 2022. The primary objective of this training session is to acquire practical knowledge about the diagnostic investigation and treatment of Ataxias through a series of didactic talks by clinicians who have significant experience in this area. Attendees are introduced to ongoing research in the field of Ataxia and have the ability to personally interact with patients and families affected by a wide spectrum of Ataxic disorders. The ACT includes topics on diagnostic approaches to Ataxias, heredodegenerative and Acquired Ataxias, neurogenetics of Ataxias, treatment of Ataxia, and research on Ataxia.
ACT provides attendees with the ability to interact with Ataxia experts, many of whom are reputable clinicians and scientists, and explore opportunities for specializing in this field. There is a need for new talent and ideas, given we are ushering in an era of cutting-edge molecular, biopharmaceutical, and bioengineering tools that hold significant promise for the cure of neurodegenerative disorders. The highlight of ACT is interactions between attendees and patients affected by a wide spectrum of Ataxic disorders. Very few conferences offer the opportunity to bolster didactic knowledge with clinical experience making this course unique in its training scope.
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.